Skip to main content
SpringerLink
Log in

Observation of the curative effect of Mabthera in combination with the CHOP regimen in treating invasive B-cell lymphoma: A report of 45 cases

  • Published:
Chinese Journal of Clinical Oncology

Abstract

Objective

To observe the clinical efficacy and toxic effects of Mabthera (rituximab) in combination with the CHOP (R-CHOP) regimen for treating invasive B-cell non-Hodgkin’s lymphoma.w

Methods

A total of 45 patients with CD20 positive B-cell non-Hodgkin’s lymphoma were randomly divided into the R-CHOP (22 cases) and CHOP groups (23 cases for controls). They received the regimens of Mabthera in combination with CHOP or single CHOP therapy respectively. An appraisement of the curative effect could only be performed following 4 cycles of chemotherapy for the 45 patients. Follow-up was conducted to observe the conditions of survival.

Results

The rate of complete remission (CR) in the R-CHOP group was 68.2%, with a total effective rate of 81.8%, and in the CHOP group these rates were 34.8% and 78.3% respectively. There was a significant difference in comparing the CR rates between the two groups (P < 0.05). The 1, 2 and 3-year overall survival (OS) rates of the RCHOP group were 90.9%, 81.8% and 77.3%, respectively. In the CHOP group, the OS rates were respectively 91.3%, 69.5% and 47.8%. The difference in the 3-year OS between the two groups was significant (P < 0.05).

The toxic effects of the two groups were mainly a slight and moderate bone marrow depression and a gastrointesinal reaction, with similar tolerable toxic effects in the two groups (P > 0.05). Adverse effects related to the Mabthera infusions occurred in 6 cases of the R-CHOP group (27.2%). These effects lessened after symptomatic treatment.

Conclusion

The therapeutic regimen of Mabthera, in combination with CHOP (R-CHOP) has an obvious curative effect for treating invasive B-cell non-Hodgkin’s lymphoma, with a favorable tolerance. It is highly recommended as the treatment of choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jiang WQ, Sun XF, Zhang L, et al. Ed. Practical Manual of Medical Oncology Prescription. Guangzhou: Guangdong Science Publishing House 2003; 316–317 (Chinese).

    Google Scholar 

  2. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A Study by the Groupe d’Etude des Lymphomes de l’Adulte. Clin Oncol 2005; 23: 4117–4126.

    Article  CAS  Google Scholar 

  3. Pfreundschuh M, Trümper L, Osterborq A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391.

    Article  PubMed  CAS  Google Scholar 

  4. Glass B, Kloess M, Benter M, et al. Dose-escalted CHOP plus etoposide (Mega CHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin’s Lymphoma. Blood 2006; 107: 3058–3064.

    Article  PubMed  CAS  Google Scholar 

  5. Zhou JC. Ed. Practical Medical Oncology. Beijing: People’s Medical Publishing House 2003; 29–47 (Chinese).

    Google Scholar 

  6. Jiang WQ, Zhang XS, Zhu XF, et al. Biotherapeutics of Oncology. Guangzhou: Guangdong Science Publishing House 2006; 13–14.

    Google Scholar 

  7. Lu YQ, He QH, Xu J, et al. In vitro induction of rituximab on apoptosis of Daudi cells. Zhonghua Xue Ye Xue Za Zhi 2002; 23: 206–207 (Chinese).

    Google Scholar 

  8. Maloney DG, Grillo-lopez A J, White CA, et al. Rituximab anti-CD20 mommclonal antibody therapy in patients with relepsed low-grade non-Hodgkin’s Lymphoma. Blood 1997; 90: 2188–2195.

    PubMed  CAS  Google Scholar 

  9. Jermann M, Jost LM, Taverna CH, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004; 15: 511–516.

    Article  PubMed  CAS  Google Scholar 

  10. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE assecond-line therapy before autologous stem cell transplantion for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688.

    Article  PubMed  CAS  Google Scholar 

  11. Vose JM, Link BK, Grossbard ML, et al. Phase 1 study of Rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin’s lymphoma. Clin Oncol 2001; 19: 389–397.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. No.1 Department of Medical Oncology, Jiang-xi Cancer Hospital, Nanchang, 330029, Jiangxi Province, China

    Yuerong Shuang, Daqian Ye, Jianxiang Chen, Yaohua Wu, Hui Huang & Guanghua Fan

Authors
  1. Yuerong Shuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daqian Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianxiang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yaohua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guanghua Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuerong Shuang.

About this article

Cite this article

Shuang, Y., Ye, D., Chen, J. et al. Observation of the curative effect of Mabthera in combination with the CHOP regimen in treating invasive B-cell lymphoma: A report of 45 cases. Chin. J. Clin. Oncol. 5, 215–218 (2008). https://doi.org/10.1007/s11805-008-0215-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11805-008-0215-z

Key Words

Search

Navigation